Lower risk of peripheral venous catheter-related bloodstream infection by hand insertion.


Journal

Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411

Informations de publication

Date de publication:
03 06 2022
Historique:
received: 19 01 2022
accepted: 20 05 2022
entrez: 6 6 2022
pubmed: 7 6 2022
medline: 9 6 2022
Statut: epublish

Résumé

Little is known about the bloodstream infection (BSI) risk associated with short-term peripheral venous catheters (PVCs) and no large study investigated the insertion site-related risk for PVC-BSI. We performed a cohort study at the University of Geneva Hospitals using the prospective hospital-wide BSI surveillance database. We analyzed the association between insertion site and risk of PVC-BSI on the upper extremity using univariable and multivariable marginal Cox models. Between 2016 and 2020, utilization of 403'206 peripheral venous catheters were prospectively recorded in a 2000-bed hospital consortium with ten sites. Twenty-seven percent of PVC (n = 109'686) were inserted in the hand. After adjustment for confounding factors, hand insertion was associated with a decreased PVC-BSI risk (adjusted hazard ratio [HR] 0.42, 95% CI 0.18-0.98, p = 0.046) compared to more proximal insertion sites. In a sensitivity analysis for PVCs with ≥ 3 days of dwell time, we confirmed a decreased PVC-BSI risk after hand insertion (HR 0.37, 95% CI 0.15-0.93, p = 0.035). Hand insertion should be considered for reducing PVC infections, especially for catheters with an expected dwell time of more than 2 days.

Identifiants

pubmed: 35659775
doi: 10.1186/s13756-022-01117-8
pii: 10.1186/s13756-022-01117-8
pmc: PMC9164319
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

80

Informations de copyright

© 2022. The Author(s).

Références

J Hosp Med. 2018 May 30;13(5):
pubmed: 29813140
Prof Inferm. 2017 Jan-Mar;70(1):51-60
pubmed: 28485909
Clin Infect Dis. 2017 Oct 30;65(10):1757-1762
pubmed: 29020252
Infect Control Hosp Epidemiol. 2011 Jun;32(6):579-83
pubmed: 21558770
Clin Infect Dis. 2011 May;52(9):e162-93
pubmed: 21460264
Cochrane Database Syst Rev. 2019 Jan 23;1:CD007798
pubmed: 30671926
Crit Care Med. 2012 Jun;40(6):1707-14
pubmed: 22488003
Rev Esp Quimioter. 2013 Mar;26(1):21-9
pubmed: 23546458
J Infus Nurs. 2012 Jul-Aug;35(4):230-40
pubmed: 22759827
JAMA Intern Med. 2021 Nov 1;181(11):1471-1478
pubmed: 34533191

Auteurs

Niccolò Buetti (N)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Service PCI, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland. niccolo.buetti@gmail.com.
UMR 1137, IAME, INSERM, Université de Paris, 75018, Paris, France. niccolo.buetti@gmail.com.

Mohamed Abbas (M)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Service PCI, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.
MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK.

Didier Pittet (D)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Service PCI, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.

Marie-Noëlle Chraiti (MN)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Service PCI, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.

Valérie Sauvan (V)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Service PCI, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.

Marlieke E A De Kraker (MEA)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Service PCI, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.

Matthieu Boisson (M)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Service PCI, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.

Daniel Teixeira (D)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Service PCI, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.

Walter Zingg (W)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Service PCI, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Stephan Harbarth (S)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Service PCI, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH